Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Many economists expect muted U.S. economic growth in the coming quarters, and the first quarter's negative GDP growth makes a mild recession a real possibility. It may become difficult for ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

Palatin Technologies Inc (PTNT) reports significant progress in clinical trials and cost reductions, despite facing financial ...

CRSP spreads trades over five days to mitigate market-impact costs at each quarterly rebalance. These unique steps should reduce unnecessary trading costs and marginally improve returns over time.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Not only do chronic diseases have a devastating impact on the quality of patients ... overall as competition increases and the size of the market expands, improving patient access to key drugs.

Drugmaker AstraZeneca has teamed up with Indian digital health specialist Qure.ai and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists ...